Phathom Pharmaceuticals (PHAT) Short term Debt (2020 - 2021)
Phathom Pharmaceuticals (PHAT) reported Short term Debt of $10.3 million for Q2 2021, up 644.78% year-over-year from $1.4 million in Q2 2020, and down 12.07% quarter-over-quarter from $11.8 million in Q1 2021.
Phathom Pharmaceuticals (PHAT) Short term Debt (2020 - 2021) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has 2 years of Short term Debt data on file, last reported at $10.3 million in Q2 2021.
- Short term Debt for Q2 2021 came in at $10.3 million, up 644.78% year-over-year; the trailing twelve-month figure through Jun 2021 was $10.3 million (up 644.78% YoY), and the FY2020 annual result was $7.4 million, changed N/A from the prior year.
- Short term Debt fell to $10.3 million in Q2 2021 per PHAT's latest filing, from $11.8 million in the prior quarter.
- Over five years, Short term Debt peaked at $11.8 million in Q1 2021 and troughed at $1.4 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Phathom Pharmaceuticals | 895.99 Mn | 712.23 Mn | 46.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 10.35 Mn |
| Mar 31, 2021 | 11.77 Mn |
| Dec 31, 2020 | 7.35 Mn |
| Sep 30, 2020 | 5.56 Mn |
| Jun 30, 2020 | 1.39 Mn |